These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34006359)

  • 41. Treatment of primary chylomicronemia due to familial hypertriglyceridemia by omega-3 fatty acids.
    Richter WO; Jacob BG; Ritter MM; Schwandt P
    Metabolism; 1992 Oct; 41(10):1100-5. PubMed ID: 1406295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.
    Meyers CD; Tremblay K; Amer A; Chen J; Jiang L; Gaudet D
    Lipids Health Dis; 2015 Feb; 14():8. PubMed ID: 25889044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
    Gallo A; Béliard S; D'Erasmo L; Bruckert E
    Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Heparin and insulin in the treatment of acute hypertriglyceridemia-induced pancreatitis].
    Henzen C; Röck M; Schnieper C; Heer K
    Schweiz Med Wochenschr; 1999 Sep; 129(35):1242-8. PubMed ID: 10499250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Effect of a Fat-Restricted Diet in Four Patients with Familial Chylomicronemia Syndrome: A Long-Term Follow-Up Study.
    Thajer A; Skacel G; de Gier C; Greber-Platzer S
    Children (Basel); 2021 Nov; 8(11):. PubMed ID: 34828789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia.
    Goldenberg NM; Wang P; Glueck CJ
    Clin Chim Acta; 2003 Jun; 332(1-2):11-9. PubMed ID: 12763274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel therapeutics in hypertriglyceridaemia and chylomicronaemia.
    García Díaz JD
    Med Clin (Barc); 2020 Apr; 154(8):308-314. PubMed ID: 31932043
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Triglyceride metabolism and classification of hypertriglyceridemias.
    Ibarretxe D; Masana L
    Clin Investig Arterioscler; 2021 May; 33 Suppl 2():1-6. PubMed ID: 34006348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chylomicronaemia--current diagnosis and future therapies.
    Brahm AJ; Hegele RA
    Nat Rev Endocrinol; 2015 Jun; 11(6):352-62. PubMed ID: 25732519
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The burden of familial chylomicronemia syndrome in Canadian patients.
    Gaudet D; Stevenson M; Komari N; Trentin G; Crowson C; Hadker N; Bernard S
    Lipids Health Dis; 2020 Jun; 19(1):120. PubMed ID: 32487261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The burden of familial chylomicronemia syndrome from the patients' perspective.
    Gelrud A; Williams KR; Hsieh A; Gwosdow AR; Gilstrap A; Brown A
    Expert Rev Cardiovasc Ther; 2017 Nov; 15(11):879-887. PubMed ID: 28847199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipoprotein lipase activity and mass, apolipoprotein C-II mass and polymorphisms of apolipoproteins E and A5 in subjects with prior acute hypertriglyceridaemic pancreatitis.
    Coca-Prieto I; Valdivielso P; Olivecrona G; Ariza MJ; Rioja J; Font-Ugalde P; García-Arias C; González-Santos P
    BMC Gastroenterol; 2009 Jun; 9():46. PubMed ID: 19534808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypertriglyceridaemia in adolescents may have serious complications.
    Korf M; Zöllner EW; Solomon GEA; Zemlin AE; Marais AD
    S Afr Med J; 2022 Apr; 112(5):307-312. PubMed ID: 35587241
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prophylactic therapeutic plasma exchange in pregnant woman with Familial Chylomicronemia Syndrome - A case report.
    Pećin I; Leskovar D; Šabić M; Perica D; Šućur N; Godan Hauptman A; Merćep I; Borovečki F; Premužić V; Jelaković B; Reiner Ž
    Transfus Apher Sci; 2022 Jun; 61(3):103346. PubMed ID: 34924316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-Alcoholic Fatty Liver in Patients with Chylomicronemia.
    Maltais M; Brisson D; Gaudet D
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33572376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.
    Oral EA; Garg A; Tami J; Huang EA; O'Dea LSL; Schmidt H; Tiulpakov A; Mertens A; Alexander VJ; Watts L; Hurh E; Witztum JL; Geary RS; Tsimikas S
    J Clin Lipidol; 2022; 16(6):833-849. PubMed ID: 36402670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins.
    Visser J; van Zwol W; Kuivenhoven JA
    Curr Atheroscler Rep; 2022 Jan; 24(1):1-12. PubMed ID: 35107764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II.
    Fojo SS; Brewer HB
    J Intern Med; 1992 Jun; 231(6):669-77. PubMed ID: 1619390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. THE PREVALENCE OF PROBABLE FAMILIAL CHYLOMICRONEMIA SYNDROME IN A SOUTHERN CALIFORNIA POPULATION.
    Tripathi M; Wong A; Solomon V; Yassine HN
    Endocr Pract; 2021 Jan; 27(1):71-76. PubMed ID: 33475504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.